Lee Hambright
Stock Analyst at Bernstein
(4.32)
# 411
Out of 4,981 analysts
26
Total ratings
85%
Success rate
11.69%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $97 → $98 | $94.03 | +4.22% | 3 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $138 → $144 | $133.73 | +7.68% | 5 | Apr 17, 2025 | |
| PODD Insulet | Initiates: Outperform | $300 | $341.78 | -12.22% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $12.27 | +242.30% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $76.22 | +12.83% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $102.71 | -2.64% | 1 | Oct 24, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $449.68 | -18.83% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $103.08 | +47.46% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $178.06 | +2.77% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $383.34 | -23.04% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $77.57 | +74.04% | 3 | Mar 16, 2022 |
Medtronic
Aug 20, 2025
Maintains: Outperform
Price Target: $97 → $98
Current: $94.03
Upside: +4.22%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $138 → $144
Current: $133.73
Upside: +7.68%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $341.78
Upside: -12.22%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $12.27
Upside: +242.30%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $76.22
Upside: +12.83%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $102.71
Upside: -2.64%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $449.68
Upside: -18.83%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $103.08
Upside: +47.46%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $178.06
Upside: +2.77%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $383.34
Upside: -23.04%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $77.57
Upside: +74.04%